Rosty Raykov Sells 10,000 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock

Fennec Pharmaceuticals Inc (NASDAQ:FENC - Get Free Report) Director Rosty Raykov sold 10,000 shares of the firm's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $6.08, for a total value of $60,800.00. Following the completion of the sale, the director now directly owns 83,863 shares in the company, valued at approximately $509,887.04. This represents a 10.65 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Rosty Raykov also recently made the following trade(s):

• On Thursday, December 5th, Rosty Raykov sold 796 shares of Fennec Pharmaceuticals stock. The stock was sold at an average price of $6.04, for a total transaction of $4,807.84.
• On Monday, November 4th, Rosty Raykov sold 2,431 shares of Fennec Pharmaceuticals stock. The shares were sold at an average price of $4.31, for a total value of $10,477.61.

Fennec Pharmaceuticals Trading Up 0.3 %

FENC traded up $0.02 during mid-day trading on Tuesday, hitting $6.10. The stock had a trading volume of 61,823 shares, compared to its average volume of 90,081. The stock's fifty day simple moving average is $5.51 and its 200-day simple moving average is $5.52. The firm has a market capitalization of $167.57 million, a price-to-earnings ratio of -60.99 and a beta of 0.34. Fennec Pharmaceuticals Inc has a 1-year low of $3.96 and a 1-year high of $11.49. The company has a debt-to-equity ratio of 9.86, a current ratio of 7.80 and a quick ratio of 7.64.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Franklin Resources Inc. raised its position in shares of Fennec Pharmaceuticals by 18.7% during the third quarter. Franklin Resources Inc. now owns 14,799 shares of the company's stock worth $74,000 after purchasing an additional 2,330 shares during the period. State Street Corp raised its holdings in Fennec Pharmaceuticals by 2.2% during the 3rd quarter. State Street Corp now owns 328,259 shares of the company's stock worth $1,641,000 after buying an additional 7,053 shares during the period. Acadian Asset Management LLC bought a new position in Fennec Pharmaceuticals in the second quarter valued at approximately $49,000. Rhumbline Advisers boosted its holdings in shares of Fennec Pharmaceuticals by 44.7% in the second quarter. Rhumbline Advisers now owns 29,110 shares of the company's stock valued at $178,000 after buying an additional 8,987 shares during the period. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Fennec Pharmaceuticals during the second quarter worth $69,000. 55.51% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

FENC has been the topic of a number of analyst reports. HC Wainwright reissued a "buy" rating and issued a $13.00 target price on shares of Fennec Pharmaceuticals in a research note on Tuesday, December 17th. Wedbush reiterated an "outperform" rating and set a $13.00 price target on shares of Fennec Pharmaceuticals in a research report on Friday, December 20th. Finally, Stephens upgraded Fennec Pharmaceuticals to a "strong-buy" rating in a report on Monday, November 18th.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.